GMS Ventures & Investments
Insider CIK 1804598 · OTLK Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | P Buy deriv | 2026-08-12 | 2026-08-14 | 2,525,252 | — | $0 | 2,525,252 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy | 2026-08-12 | 2026-08-14 | 2,525,252 | $0.99 | $2.50M | 24,617,320 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy deriv | 2026-08-12 | 2026-08-14 | 2,525,252 | — | $0 | 2,525,252 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy | 2026-08-12 | 2026-08-14 | 2,525,252 | $0.99 | $2.50M | 24,617,320 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy deriv | 2026-05-28 | 2026-06-01 | 8,571,428 | — | $0 | 8,571,428 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy deriv | 2026-05-28 | 2026-06-01 | 3,458,571 | — | $0 | 3,458,571 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | H Expire deriv | 2026-05-28 | 2026-06-01 | 3,458,571 | — | $0 | 0 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | H Expire deriv | 2026-05-28 | 2026-06-01 | 8,571,428 | — | $0 | 0 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | H Expire deriv | 2026-05-28 | 2026-06-01 | 3,458,571 | — | $0 | 0 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy deriv | 2026-05-28 | 2026-06-01 | 3,458,571 | — | $0 | 3,458,571 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy | 2026-05-28 | 2026-06-01 | 8,539,709 | $0.59 | $5.04M | 22,092,068 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2025-05-27 | 2025-05-28 | 8,571,428 | — | $0 | 8,571,428 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award | 2025-05-27 | 2025-05-28 | 4,285,714 | $1.40 | $6.00M | 13,552,359 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2025-01-17 | 2025-01-22 | 3,458,571 | — | $0 | 3,458,571 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | D To issuer deriv | 2025-01-17 | 2025-01-22 | 3,458,571 | — | $0 | 0 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2025-01-17 | 2025-01-22 | 3,458,571 | — | $0 | 3,458,571 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2025-01-17 | 2025-01-22 | 3,458,571 | — | $0 | 3,458,571 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | M Exercise deriv | 2025-01-17 | 2025-01-22 | 3,458,571 | — | $0 | 0 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | M Exercise | 2025-01-17 | 2025-03-12 | 3,458,571 | $2.51 | $8.68M | 9,266,645 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2024-03-18 | 2024-03-20 | 3,458,571 | — | $0 | 3,458,571 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award | 2024-03-18 | 2024-03-20 | 2,305,714 | — | $0 | 5,808,074 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award | 2022-12-28 | 2022-12-29 | 14,230,418 | $0.88 | $12.52M | 70,047,204 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | J Other | 2022-04-21 | 2022-07-07 | 27,982,529 | — | $0 | 55,816,786 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | J Other | 2022-04-21 | 2022-04-22 | 27,982,529 | — | $0 | 55,816,786 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | J Other | 2022-02-01 | 2022-02-01 | 2,500,000 | $1.25 | $3.13M | 27,982,529 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy | 2021-11-29 | 2021-12-01 | 16,000,000 | $1.25 | $20.00M | 27,834,257 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award | 2021-02-10 | 2021-02-11 | 1,013,627 | $1.00 | $1.01M | 11,834,257 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | P Buy | 2021-02-02 | 2021-02-02 | 8,360,000 | $1.00 | $8.36M | 10,820,630 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award deriv | 2020-02-26 | 2020-02-27 | 1,230,315 | $0.13 | $159.9K | 1,230,315 | SEC↗ |
| OTLK Outlook Therapeutics, Inc. | A Award | 2020-02-26 | 2020-02-27 | 2,460,630 | $1.02 | $2.51M | 2,460,630 | SEC↗ |